Open Access

In critically ill patients the procalcitonin level can be misleading

  • Jacqueline Koeze1Email author,
  • MG Ron Hendrix2,
  • Frank AJTM van den Bergh3,
  • René ML Brouwer4 and
  • Jan G Zijlstra1
Critical Care201115:422

DOI: 10.1186/cc10132

Published: 28 April 2011

Three recently published articles in Critical Care concerning the usefulness of procalcitonin (PCT) in critically ill patients elicited this cautionary comment of the present article's title [13]. PCT has been introduced as a test with high sensitivity and specificity for bacterial infection in patients in the emergency department. The test's negative predictive value is thought to be sufficient to withhold antibiotics in cases of low PCT [4, 5]. PCT has also been evaluated as a diagnostic tool in critically ill patients. This would be of help because there is no immediately available test that proves or disproves a bacterial infection. Especially, the number of true and false negative patients cannot be estimated. We therefore cannot determine the test characteristics of PCT in these patients. We can determine with more certainty the true positive patients and measure their PCT level.

Between March 2007 and April 2008 we registered all patients presenting to the emergency department, the ICU or wards of internal medicine meeting the criteria of the Surviving Sepsis Campaign guidelines for severe sepsis or septic shock. In these patients we measured the PCT level with the PCT-Q test (Brahms, Henningsdorf, Germany) at presentation, and microbiological analysis (blood cultures, sputum cultures and urine cultures) was performed. Microbiological proven sepsis was defined by a positive blood culture result (except cultures with Staphylococcus epidermidis) or by positive culture results other than blood in the presence of two or more systemic inflammatory response syndrome criteria.

In the above-mentioned period we included 132 patients. Patient characteristics are displayed in Table 1. A total of 63 (47%) patients had proven sepsis or septic shock. Blood cultures were taken in 127 patients, of which 40 patients (30.3%) were positive. In 101 patients with blood cultures taken, the PCT level was measured at presentation (Table 2). Thirty-two patients had PCT levels <0.5 ng/ml, of which eight patients (25%) had positive blood cultures.
Table 1

Characteristics of the 132 patients included in the analysis

Number of patients (n)

132

Age (years)a

65.3 ± 1.3

(22.7 to 96.0)

Male (%)

64.4

Survival (%)

74.2

PCT analysis at presentation performed (n)

110

Number of patients with PCT <0.5 ng/ml (n (%))

34 (25.8)

Number of patients with PCT 0.5 to 2.0 ng/ml (n (%))

21 (21.2)

Number of patients with PCT 2.0 to 10.0 ng/ml (n (%))

27 (20.5)

Number of patients with PCT >10.0 ng/ml (n (%))

28 (21.2)

Number of blood cultures conducted (% positive findings)

127 (30.3)

Number of sputum cultures conducted (% positive findings)

24 (33.3)

Number of urine cultures conducted (% positive findings)

79 (25.3)

Number of pus cultures conducted (% positive findings)

26 (65.4)

PCT, procalcitonin. aData presented as mean ± standard error of the mean (range).

Table 2

Procalcitonin results in negative and positive blood cultures

 

Blood cultures (n)

 

Procalcitonin at presentation

Negative

Positive

Total (n)

<0.5 ng/ml

24

8

32

0.5 to 2.0 ng/ml

16

5

21

2.0 to 10.0 ng/ml

13

10

23

>10.0 ng/ml

12

13

25

Total

65

36

101

Based on these results we conclude that PCT levels can be misleading. It is unsafe to withhold antibiotics based on a test with unknown test characteristics, such as PCT, in patients presenting with criteria meeting the Surviving Sepsis Campaign guidelines for severe sepsis or septic shock. Fortunately, the Surviving Sepsis Campaign bundle is clear on this point and these patients received appropriate antibiotics in accordance with this guideline.

Abbreviations

ICU: 

intensive care unit

PCT: 

procalcitonin.

Declarations

Authors’ Affiliations

(1)
Department of Critical Care, University of Groningen,University Medical Center Groningen
(2)
Twente Achterhoek, Laboratory of Microbiology
(3)
Department of Clinical Chemistry, Medisch Spectrum Twente
(4)
Department of Internal Medicine, Medisch Spectrum Twente

References

  1. Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, Kolho E, Ruokonen E, Finnsepsis Study Group: Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010, 14: R205. 10.1186/cc9327PubMed CentralView ArticlePubMed
  2. van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, van Dissel JT: Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010, 14: R206. 10.1186/cc9328PubMed CentralView ArticlePubMed
  3. Wolff M, Bouadma L: What procalcitonin brings to management of sepsis in the ICU. Crit Care 2010, 14: 1007. 10.1186/cc9330PubMed CentralView ArticlePubMed
  4. Bouadma L, Luyt CE, Tuback F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasochi S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brum-Buisson C, Chastre J, Wolff M: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomized controlled trial. Lancet 2010, 375: 463-474. 10.1016/S0140-6736(09)61879-1View ArticlePubMed
  5. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Apmaganidis A: Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010, 38: 2229-2241. 10.1097/CCM.0b013e3181f17bf9View ArticlePubMed

Copyright

© BioMed Central Ltd 2011

Advertisement